Press Office

Blood cancer

Blood cancer manipulates immune cells to survive

Published on: 13 February 2023

The most comprehensive study to date of the blood cancer, Hodgkin lymphoma, has provided fascinating insights into what tumour cells must do to survive.

Researchers from the Wellcome Sanger Institute, involving Newcastle University, found that cancer cells use signals to attract certain types of immune cell and instruct them not to attack.

The study, published in Blood, also found that high concentrations of these cell clusters in existing sample data predicted the failure of chemotherapy.

This knowledge could be used to move towards precision medicine and identify patients who may benefit from newer immune-based therapies, which are more effective in cases where traditional treatments have failed.

Lymphatic system

Hodgkin lymphoma is a cancer of the lymphatic system, an important part of the human immune system that plays a role in fighting infections and destroying abnormal cells.

The condition is typified by the presence of Hodgkin / Reed-Sternberg cells, a type of white blood cell called a B lymphocyte that has become cancerous. B lymphocytes normally make antibodies to help fight infections.

Hodgkin lymphoma is a cancer with around 2,100 diagnoses in the UK each year. Though most patients respond well to chemotherapy, radiotherapy, or a combination of both, for some these treatments fail.

In the new study, researchers combined multiple approaches to investigate the immune microenvironment around Hodgkin lymphoma tumours in unprecedented detail.

Single-cell sequencing and spatial transcriptomic data from Hodgkin lymphoma and healthy lymph node tissue were generated at the Wellcome Sanger Institute, to identify the genes expressed by each cell and their position in relation to their neighbours.

This was combined with microscope imaging data from Hodgkin lymphoma biopsies from Newcastle University.

Analysis of single-cell data revealed that cancer cells were surrounded by clusters of macrophages, monocytes and cDC2 dendritic cells, which are all types of immune cell. Imaging data showed that these cells expressed molecules that suppressed their anti-tumour capabilities.

Dr Chris Carey, a senior author of the study from Newcastle University, said: “Understanding how Hodgkin lymphoma tumours bypass the body’s immune response opens new possibilities to treat this disease.

“If we could identify which patients have higher concentrations of these immune cell clusters around the tumour, for example, we could tailor their treatments, limiting the effects of chemotherapy for patients in whom it is less likely to work and proceeding directly to immune-based therapies that stand a better chance.”

Distinct ‘microenvironments’

Researchers noted two distinct ‘microenvironments’ around cancer cells that gave indications as to how successful traditional treatments would be.

High concentrations of immune cell clusters around cancer cells were predictive of treatment failure, whereas a microenvironment showing high concentrations of stromal cells was associated with treatment success.

Because stromal cells indicate that tissue has been previously repaired, it may be that the immune system had already been partially successful in fighting the disease – with treatment providing a helping hand to eradicate the cancer entirely.

The cellular messaging used by the cancer cells to manipulate immune cells is also a potential drug target. Disrupting this signalling would in theory allow the immune system to respond as it should and attack the cancer cells.

Dr Ben Stewart, first author of the study from the Wellcome Sanger Institute, said: “This study is a great example of how much information we can get out of one tissue sample.

“By combining single-cell, spatial transcriptome and histological data, we were able to learn how precisely Hodgkin lymphoma manages to evade immune response.

“You could think of this approach as a sort of roadmap for molecular pathology, which could be applied to other diseases as well.”

Press release adapted with thanks to the Wellcome Sanger Institute


Latest News